For Rare and Rapidly Progressing Disease US FDA Has Heard ‘Well and Clear’ Placebo Is Unacceptable

Remarks at the NORD Breakthrough Summit from the FDA’s Lola Fashoyin-Aje may suggest the agency is becoming more comfortable with single-arm trials.